Related Experiment Videos
Terbutaline depot tablets in asthma. A clinical evaluation
Allergy
|October 1, 1981
Summary
New sustained-release terbutaline sulfate tablets offer comparable asthma symptom control to standard tablets. The twice-daily dosing of Bricanyl depot tablets improves patient compliance and may provide a more stable therapeutic effect.
Area of Science:
- Pharmacology
- Clinical Medicine
- Respiratory Medicine
Background:
- Asthma management often requires frequent medication.
- Improving patient compliance is crucial for effective long-term treatment.
- Terbutaline sulfate is a bronchodilator used for asthma.
Purpose of the Study:
- To evaluate the efficacy and safety of a new sustained-release formulation of terbutaline sulfate (Bricanyl depot tablets).
- To compare the effects and side effects of terbutaline depot tablets (7.5 mg twice daily) with standard terbutaline tablets (5 mg three times daily).
Main Methods:
- A double-blind, cross-over, double-dummy, randomized clinical trial.
- Patients with perennial asthma requiring daily medication participated.
- The study involved two consecutive 7-day treatment periods.
Main Results:
- The efficacy of terbutaline depot tablets was found to be equivalent to that of ordinary terbutaline tablets.
- No significant differences in side effects were highlighted in the summary.
Conclusions:
- Sustained-release terbutaline sulfate offers a viable alternative for asthma treatment with improved patient compliance due to twice-daily dosing.
- The stable plasma concentration from depot tablets may benefit patients with unstable asthma or morning dips in peak expiratory flow (PEF).